Incannex Healthcare Updates Principal Executive Offices
Ticker: IXHL · Form: 8-K · Filed: Jan 24, 2024 · CIK: 1873875
| Field | Detail |
|---|---|
| Company | Incannex Healthcare Inc. (IXHL) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, address-change
TL;DR
**Incannex Healthcare just updated its official business address in an 8-K.**
AI Summary
Incannex Healthcare Inc. filed an 8-K on January 24, 2024, to update its principal executive offices to Suite 105, 8 Century Circuit, Norwest, NSW 2153, Australia. This administrative change reflects a new physical location for the company's main operations. For investors, this matters because it provides current contact information and confirms the company's operational base, which can be important for due diligence and understanding the company's geographic focus.
Why It Matters
This filing provides updated contact information for Incannex Healthcare Inc., ensuring transparency and accurate record-keeping for investors and regulators.
Risk Assessment
Risk Level: low — This filing is purely administrative, reporting a change of address, and does not indicate any operational or financial risks.
Analyst Insight
Smart investors should update their records with the new contact information for Incannex Healthcare Inc. and recognize this as a routine administrative update with no immediate impact on investment thesis.
Key Players & Entities
- Incannex Healthcare Inc. (company) — the registrant filing the 8-K
- January 24, 2024 (date) — date of report
- Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia (address) — new principal executive offices
- +61 409 840 786 (phone_number) — registrant's telephone number
- Nasdaq Stock Market LLC (company) — exchange where common stock is registered
FAQ
What is the primary purpose of Incannex Healthcare Inc.'s 8-K filing dated January 24, 2024?
The primary purpose of Incannex Healthcare Inc.'s 8-K filing dated January 24, 2024, is to report a change in its principal executive offices, as indicated under 'ITEM INFORMATION: Other Events'.
What is the new address for Incannex Healthcare Inc.'s principal executive offices?
The new address for Incannex Healthcare Inc.'s principal executive offices is Suite 105, 8 Century Circuit, Norwest, NSW 2153, Australia, as stated in the filing.
What is the registrant's telephone number, including the area code, as provided in the filing?
The registrant's telephone number, including the area code, is +61 409 840 786, according to the filing.
On which stock exchange is Incannex Healthcare Inc.'s Common Stock, $0.0001 par value per share, registered?
Incannex Healthcare Inc.'s Common Stock, $0.0001 par value per share, is registered on The Nasdaq Stock Market LLC, as specified under 'Securities registered pursuant to Section 12(b) of the Act'.
What was the former name of Incannex Healthcare Inc. before its name change on July 20, 2021?
The former name of Incannex Healthcare Inc. was Incannex Healthcare Ltd, with the date of name change being 20210720, as listed under 'FORMER COMPANY' data.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-01-24 16:30:18
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IXHL The Nasdaq
Filing Documents
- ea192100-8k_incannex.htm (8-K) — 26KB
- ea192100ex99-1_incannex.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-006119.txt ( ) — 226KB
- ixhl-20240124.xsd (EX-101.SCH) — 3KB
- ixhl-20240124_lab.xml (EX-101.LAB) — 33KB
- ixhl-20240124_pre.xml (EX-101.PRE) — 22KB
- ea192100-8k_incannex_htm.xml (XML) — 3KB
01
Item 8.01 On January 24, 2024, Incannex Healthcare Inc. announced that it has commenced dosing in the Phase 2 clinical trial to assess the safety and efficacy of proprietary combination drug candidate IHL-675A in patients with rheumatoid arthiritis. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Incannex Healthcare Inc., dated January 24, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Incannex Healthcare Inc. Date: January 24, 2024 /s/ Joel Latham Name: Joel Latham Title: Chief Executive Officer and President 2